Treatment of retinal pigment epithelial detachment with antiangiogenic therapy

PURPOSE: Evaluate the efficacy of pegaptanib, a selective anti-vascular endothelial growth factor (VEGF) agent, and bevacizumab, a nonselective anti-VEGF agent, for retinal pigment epithelial detachment (PED) associated with occult choroidal neovascularization (CNV) secondary to age-related macular...

Descripción completa

Detalles Bibliográficos
Autor principal: Arias, Luis
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861946/
https://www.ncbi.nlm.nih.gov/pubmed/20463807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861946/
https://www.ncbi.nlm.nih.gov/pubmed/20463807

Ejemplares similares